About Zynerba Pharmaceuticals
Zynerba Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on developing and commercializing synthetic cannabinoid therapeutics formulated for transdermal delivery. The Company is evaluating approximately two product candidates, ZYN002 and ZYN001, in over five indications. The Company intends to study ZYN002 in patients with refractory epilepsy, osteoarthritis and Fragile X syndrome. The Company's ZYN002 is synthetic cannabidiol (CBD) formulated as a permeation-enhanced gel for transdermal delivery. ZYN002 is being developed as a clear that is designed to provide controlled drug delivery with once- or twice-daily dosing. ZYN001 is a pro-drug of tetrahydrocannabinol (THC) that enables transdermal delivery through a patch. The Company intends to test the ZYN001 patch for application to the arm, back and thigh. The Company intends to study ZYN001 in patients with fibromyalgia and peripheral neuropathic pain.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Drugs - Generic
- Sub-Industry: N/A
- Exchange: NASDAQ
- Symbol: ZYNE
- Previous Close: $21.46
- 50 Day Moving Average: $19.21
- 200 Day Moving Average: $14.06
- 52-Week Range: $5.17 - $23.75
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -8.69
- P/E Growth: 0.00
- Market Cap: $220.46M
- Outstanding Shares: 9,953,000
- Beta: 4.87
- Return on Equity: -63.78%
- Return on Assets: -56.66%
Companies Related to Zynerba Pharmaceuticals:
- Current Ratio: 7.19%
- Quick Ratio: 7.19%
What is Zynerba Pharmaceuticals' stock symbol?
Zynerba Pharmaceuticals trades on the NASDAQ under the ticker symbol "ZYNE."
Where is Zynerba Pharmaceuticals' stock going? Where will Zynerba Pharmaceuticals' stock price be in 2017?
7 brokers have issued 12 month target prices for Zynerba Pharmaceuticals' stock. Their predictions range from $22.00 to $42.00. On average, they anticipate Zynerba Pharmaceuticals' share price to reach $30.43 in the next year.
When will Zynerba Pharmaceuticals announce their earnings?
Zynerba Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Monday, March, 13th 2017.
What are analysts saying about Zynerba Pharmaceuticals stock?
Here are some recent quotes from research analysts about Zynerba Pharmaceuticals stock:
According to Zacks Investment Research, "Zynerba Pharmaceuticals, Inc. is a specialty pharmaceutical company which focuses on developing and commercializing proprietary synthetic cannabinoid therapeutics formulated for transdermal delivery. Its product candidates which are in clinical trial stage include ZYN002 and ZYN001 synthetic transdermal cannabinoid therapeutics for indications including refractory epilepsy, Fragile X syndrome, osteoarthritis, fibromyalgia and peripheral neuropathic pain. Zynerba Pharmaceuticals, Inc. is headquartered in Devon, Pennsylvania. " (2/18/2017)
Oppenheimer Holdings, Inc. analysts commented, "Zynerba reported 1Q16 results on Thursday, May 12th which were largely in-line. The company continues to track to near-term catalysts in the mid- and second half 2016 timeframes. We continue to believe that the relationship between GW Pharmaceuticals’ Epidiolex program and Zynerba’s ZYN002 program will be closely linked. GW already announced positive results from its cannabidiol program in Dravet Syndrome patients in mid-March, and has additional data read-outs in 2Q16 and 3Q16. Our understanding is that there may be some concern over cannabidiol’s role in enhancing the conversion of clobazam to norclobazam, an active metabolite. One important distinction in Zynerba’s trials from GW’s is that Zynerba is excluding clobazam as a concomitant medication." (5/16/2016)
Who owns Zynerba Pharmaceuticals stock?
Zynerba Pharmaceuticals' stock is owned by a variety of of institutional and retail investors. Top institutional investors include Perceptive Advisors LLC (8.46%), J. Goldman & Co LP (0.72%) and GSA Capital Partners LLP (0.14%). Company insiders that own Zynerba Pharmaceuticals stock include James E Fickenscher, Michael Rapp and Suzanne M Hanlon.
Who bought Zynerba Pharmaceuticals stock? Who is buying Zynerba Pharmaceuticals stock?
Zynerba Pharmaceuticals' stock was purchased by a variety of institutional investors in the last quarter, including Perceptive Advisors LLC, J. Goldman & Co LP and GSA Capital Partners LLP. Company insiders that have bought Zynerba Pharmaceuticals stock in the last two years include James E Fickenscher and Michael Rapp.
How do I buy Zynerba Pharmaceuticals stock?
Shares of Zynerba Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of Zynerba Pharmaceuticals stock cost?
One share of Zynerba Pharmaceuticals stock can currently be purchased for approximately $21.46.